PT2753306T - Formas de dosagem sólidas de 2-amino-3-(4-(2-amino-6-((r)-1- (4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2- trifluoroetoxi)pirimidin-4-il)fenil)propanoato de (s)-etilo - Google Patents

Formas de dosagem sólidas de 2-amino-3-(4-(2-amino-6-((r)-1- (4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2- trifluoroetoxi)pirimidin-4-il)fenil)propanoato de (s)-etilo

Info

Publication number
PT2753306T
PT2753306T PT127806172T PT12780617T PT2753306T PT 2753306 T PT2753306 T PT 2753306T PT 127806172 T PT127806172 T PT 127806172T PT 12780617 T PT12780617 T PT 12780617T PT 2753306 T PT2753306 T PT 2753306T
Authority
PT
Portugal
Prior art keywords
phenyl
amino
propanoate
trifluoroethoxy
pyrazol
Prior art date
Application number
PT127806172T
Other languages
English (en)
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of PT2753306T publication Critical patent/PT2753306T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
PT127806172T 2011-10-17 2012-10-16 Formas de dosagem sólidas de 2-amino-3-(4-(2-amino-6-((r)-1- (4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2- trifluoroetoxi)pirimidin-4-il)fenil)propanoato de (s)-etilo PT2753306T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161547894P 2011-10-17 2011-10-17

Publications (1)

Publication Number Publication Date
PT2753306T true PT2753306T (pt) 2020-11-11

Family

ID=47116458

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127806172T PT2753306T (pt) 2011-10-17 2012-10-16 Formas de dosagem sólidas de 2-amino-3-(4-(2-amino-6-((r)-1- (4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2- trifluoroetoxi)pirimidin-4-il)fenil)propanoato de (s)-etilo

Country Status (19)

Country Link
US (4) US20130172376A1 (pt)
EP (2) EP3763374A1 (pt)
JP (1) JP6203182B2 (pt)
KR (1) KR102047788B1 (pt)
CN (1) CN103987381B (pt)
AU (1) AU2012326383B2 (pt)
BR (1) BR112014009308B1 (pt)
CA (1) CA2851862C (pt)
DK (1) DK2753306T3 (pt)
ES (1) ES2835722T3 (pt)
HU (1) HUE051585T2 (pt)
IL (1) IL231958B (pt)
MX (1) MX360191B (pt)
PL (1) PL2753306T3 (pt)
PT (1) PT2753306T (pt)
RU (1) RU2661402C2 (pt)
SG (1) SG11201401583YA (pt)
UA (1) UA114412C2 (pt)
WO (1) WO2013059146A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
CN106102877A (zh) 2014-03-28 2016-11-09 日本碍子株式会社 整体型分离膜结构体及其制造方法
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
CN108883377B (zh) 2016-03-31 2021-05-07 日本碍子株式会社 多孔质支撑体、多孔质支撑体的制造方法、分离膜结构体以及分离膜结构体的制造方法
TW201818964A (zh) 2016-09-30 2018-06-01 瑞士商諾伊曼特醫療公司 使用色胺酸羥化酶抑制劑之方法
EP3363798A1 (en) 2017-02-20 2018-08-22 Esteve Química, S.A. Amorphous form of telotristat etiprate

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9124807D0 (en) * 1991-11-22 1992-01-15 Wellcome Found Pharmaceutical formulations
PE20000559A1 (es) * 1998-05-27 2000-07-05 Merck & Co Inc Formulacion de tabletas comprimidas de efavirenz
EP1332757B1 (en) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
WO2005021000A1 (en) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Solid oral dosage forms of gatifloxacin
MX2007015571A (es) * 2005-06-09 2008-03-06 Wyeth Corp Composiciones de tanaproget que contienen etinilestradiol.
CN101528202A (zh) * 2006-07-05 2009-09-09 特瓦制药工业有限公司 美金刚的药物组合物
UA99270C2 (en) * 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
PE20090185A1 (es) * 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
TWI439457B (zh) * 2007-09-28 2014-06-01 Lexicon Pharmaceuticals Inc （ｓ）－２－胺基－３－（４－（２－胺基－６－（（ｒ）－１－（４－氯－２－（３－甲基－１ｈ－吡唑－１－基）苯基）－２，２，２－三氟乙氧）－嘧啶－４－基）苯基）丙酸乙酯之固體形式與其使用方法
WO2010056992A1 (en) * 2008-11-13 2010-05-20 The Trustees Of Columbia University In The City Of New York Methods of preventing and treating low bone mass diseases
EP2216016A1 (en) * 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
JP2012522058A (ja) * 2009-03-31 2012-09-20 リガンド・ファーマシューティカルズ・インコーポレイテッド 血圧上昇および糖尿病性腎症を処置するための、ジフェニルスルホンアミドエンドセリンおよびアンジオテンシンｉｉ受容体アゴニストの経口製剤

Also Published As

Publication number Publication date
PL2753306T3 (pl) 2021-04-06
MX360191B (es) 2018-10-24
UA114412C2 (uk) 2017-06-12
CN103987381B (zh) 2017-07-04
MX2014004603A (es) 2014-05-12
CA2851862C (en) 2020-04-14
RU2661402C2 (ru) 2018-07-16
SG11201401583YA (en) 2014-09-26
RU2014119866A (ru) 2015-11-27
JP6203182B2 (ja) 2017-09-27
US20210008068A1 (en) 2021-01-14
IL231958A0 (en) 2014-05-28
NZ717137A (en) 2017-10-27
US11406635B2 (en) 2022-08-09
IL231958B (en) 2018-06-28
AU2012326383B2 (en) 2017-07-27
AU2012326383A1 (en) 2014-04-24
HUE051585T2 (hu) 2021-03-01
DK2753306T3 (da) 2020-12-14
BR112014009308A2 (pt) 2017-04-11
US20150157632A1 (en) 2015-06-11
EP3763374A1 (en) 2021-01-13
BR112014009308B1 (pt) 2022-05-03
NZ623423A (en) 2016-04-29
JP2014532073A (ja) 2014-12-04
KR20140081872A (ko) 2014-07-01
CN103987381A (zh) 2014-08-13
EP2753306A1 (en) 2014-07-16
CA2851862A1 (en) 2013-04-25
WO2013059146A1 (en) 2013-04-25
ES2835722T3 (es) 2021-06-23
KR102047788B1 (ko) 2019-11-22
US20130172376A1 (en) 2013-07-04
US20190000843A1 (en) 2019-01-03
EP2753306B1 (en) 2020-09-23

Similar Documents

Publication Publication Date Title
IL272622A (en) Use of proton tyrosine kinase inhibitors
IL236495A0 (en) Heteroaromatic compounds as proton tyrosine kinase inhibitors
IL242279A0 (en) Compounds of 3-chloro-3]-n-(pyrimidine-2-ylamino)phenyl]substituted propanamide and their salts
IL231958B (en) Solid dosage forms of (s)-ethyl-2-amino-3-(4-(2-amino-6(r)-1-(4-chloro-2-(3-methyl-h1-pyrazol-1-yl )-2,2,2-trifluoroethoxy)pyrimidine-4-yl(phenyl)propanoate
ZA201400012B (en) Inhibitors of bruton's tyrosine kinase
IL238571A0 (en) Broton tyrosine kinase inhibitors, preparations containing them and their uses
ZA201308397B (en) Inhibitors of bruton's tyrosine kinase
IL236294A (en) 4– (Converted-Amino) –7 h– Pyrrolo [3–2, d] Pyrimidines as lrrk2 Inhibitors
SI2432472T1 (sl) 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
EP2694486A4 (en) SUBSTITUTED N- (3- (PYRIMIDIN-4-YL) PHENYL) ACRYLAMIDE ANALOGUES AS BTK TYROSINE KINASE RECEPTOR INHIBITORS
ZA201400739B (en) Inhibitors of bruton's tyrosine kinase
HK1202237A1 (zh) -二氯- -苯並 咪唑- -基 -吡唑- -羧酸的葡甲胺鹽製劑
ZA201303049B (en) Crystalline forms of (s)-2-amino-3-(4-(2- amino-6-((r)-1(4-chloro-2-(3-methyl-1h-pyrazol-1-yl) phenyl)- 2, 2, 2-trifluoroethoxy)pyrimidin-4- yl)phenyl)propanoic acid
ITMI20110647A1 (it) Procedimento migliorato per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
SI2608789T1 (sl) Terapevtske uporabe 1-(2-(2,4-dimetil-fenilsulfanil) fenil) piperazina
TH148782B (th) รูปแบบปริมาณขนาดยาชนิดแข็งที่ให้ของ (S)-เอทธิล-2-อะมิโน-3-(4-(2-อะมิโน-6-((R)-1-(4-คลอโร-2-(3-เมทธิล-1H-ไพราซอล-1-อิล)ฟีนิล)-2,2,2-ไตรฟลูออโรเอทธอกซี) ไพริมิดิน-4-อิล)ฟีนิล)โพรพาโนเอต ((S)-ethyl-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-y1)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate)
ZA201302996B (en) Solid forms of 3-(4-(aminomethyl)-1-(5-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate